Tirzepatide is already FDA-approved for diabetes (sold as Mounjaro), as well as for weight loss and now sleep apnea (sold as Zepbound)
Tirzepatide Side Effects# Well-characterized from Phase 3 (SURPASS, SURMOUNT) trials and post-market surveillance: Gastrointestinal : Nausea (12-33%), diarrhea (12-21%), vomiting (5-12%), constipation (6-11%) Decreased appetite : Common and expected pharmacological effect Injection site reactions : Mild, occurring in 2-5% of patients Pancreatitis : Rare
Although its tumoricidal properties hold therapeutic promise, its clinical application in lower gastrointestinal diseases and cancers remains challenging
But when switching between them, these half-lives determine the critical washout period you must observe
Fatty meals require more digestive effort and delay stomach emptying even further, compounding nausea and bloating